Vonoprazan Safety and Effectiveness for Reflux Esophagitis in Japan, 12-Month Study

A post-marketing surveillance study of 1,237 patients from 122 sites in Japan assessing the long-term safety and effectiveness of vonoprazan for reflux esophagitis maintenance therapy. The dataset includes safety outcomes like adverse drug reactions and effectiveness measures such as endoscopic recurrence rates. The study was authored by Noriaki Manabe and published on figshare in 2026.

Use Cases

• Analyze adverse drug reaction rates based on reported incidence and types of events.
• Model recurrence risk of reflux esophagitis based on endoscopic findings data.
• Assess symptom severity trends over time based on longitudinal symptom data.
• Evaluate real-world drug safety profiles based on post-marketing surveillance methodology.

Strengths

• Data from a prospective observational study across 122 clinical sites in Japan.
• Includes specific safety metrics: 2.3% adverse drug reaction rate and 4.0% endoscopic recurrence rate.
• Contains longitudinal data covering a 12-month treatment period.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic bias inherent to its collection solely in Japan.

Provenance

Source

figshare

Collection Method

Prospective, observational post-marketing surveillance study.

Time Range

Study duration of 12 months.

Freshness

Last updated 2026-04-15 07:33:34; freshness should be verified.

Geography

Japan